Skip to main content
. 2016 Oct 3;2:16025. doi: 10.1038/cddiscovery.2016.25

Figure 4.

Figure 4

Flow cytometry dot plots of two representative patient PBMCs: activated DCs, isolated at the baseline (a and b) and after four treatment courses with mPE doublet and bevacizumab (c and d).